Stock screenerAll disclosures →
EDGAR →
ADCT
Conviction 63HealthcareScan · Fri, Oct 9, 2026ADC Therapeutics SA (ADCT) closed at $1.73 (+8.81%) on Oct 9, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 75, RS Rating 40, -64.5% from its 52-week high, -50.8% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
ADCT$1.73+8.81%
ResistanceSupportVol 14Vol MA14 1.77M
Jul 14Jul 30Aug 18Sep 3Sep 23Oct 9
Price1.73
Change+8.81%
Gap-0.63%
Rel volume1.67×
Avg volume1.74M
Avg $ vol2.25M
SMA 201.24
SMA 501.17
SMA 2002.63
Price vs 50+48.06%
Price vs 200-34.31%
MA stackmixed
50/200 cross—
Supertrendup · 1.27
RSI (14)75
MACD hist0.05
MACD crossbull · 3d
Stoch %K / %D88 / 92
ADX (14)21
+DI / −DI43 / 12
RSI divergence—
MACD divergence—
ATR %7.45%
ADR %9.12%
52w high4.88
52w low0.9601
From 52w high-64.55%
Above 52w low+80.19%
New 52w highNo
SqueezeOff
Bollinger width56.07%
%B1.21
Donchian pos88.34%
Donchian high1.83
Donchian low1.01
AVWAP (52w high)1.83
vs AVWAP high-5.46%
AVWAP (52w low)1.15
vs AVWAP low+51.06%
OBV trendUp
Chaikin MF (20)0.37
Today vs 20d1.67×
Avg vol (14d)1.74M
Avg vol (20d)1.74M
Avg $ vol (20d)2.25M
Market cap220.87M
RS Rating40 / 99
RS 3m (vs SPY)+34.48%
RS 6m (vs SPY)-68.32%
RS line new highYes
Trend template3/8
Technical rank44.8
1 week+53.10%
1 month+55.86%
3 months+38.40%
6 months-53.74%
1 year-61.89%
YTD-50.85%
P/E-1.55
P/B-0.97
P/S3.20
P/FCF-1.56
EPS-1.12
Div yield—
ROE62.50%
ROA-51.05%
Debt/Eq-0.03
Current3.03
EV/EBITDA—
Gross margin—
Net margin-206.52%
Rev growth-7.81%
EPS growth9.64%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value7.94M
Revenue18.63M
Net income-16.57M
Gross profit—
Free cash flow-141.44M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNYSE
Shares out127.19M
Employees193
ListedFri, May 15, 2020
Free float91.04M
Float %73.5%
Short interest6.29M
Days to cover2.8d
Short volume37.7%
Squeeze score38 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeB
Conviction63 / 100
Pattern quality—
Tech rank44.8 / 100
Group rank14 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance1.37
Support0.9798
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC SaysYahoo Finance · Fri, Oct 9, 2026
- ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull ThesisSeeking Alpha · Fri, Oct 9, 2026
- $ADC Therapeutics (ADCT.US)$ outta this world im so sky high!! got a gap to fill yoMoomoo · Fri, Oct 9, 2026
- ADC Therapeutics Shares Rise After Financial Restructuring Extends Cash Runwaymarketscreener.com · Thu, Oct 8, 2026
- ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsYahoo Finance · Thu, Oct 8, 2026
- An $86.6 million financing is expected to keep ADC Therapeutics funded into 2029.Stock Titan · Thu, Oct 8, 2026
- ADC Therapeutics stock gained 8.27 percent to USD 1.38AD HOC NEWS · Wed, Oct 7, 2026
Congress activity
Disclosed STOCK Act trades in ADCT
No recent disclosed trades by Congress in ADCT. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ADCT
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Azelby Robert Director · Common Shares · 2026-06-03 | Tax | 12.6K | $39K | 2026-06-03 | 2026-06-03 |
Coughlin Timothy Director · Common Shares · 2026-06-03 | Tax | 12.6K | $39K | 2026-06-03 | 2026-06-03 |
Hug Peter Director · Common Shares · 2026-06-03 | Tax | 2.16K | $7K | 2026-06-03 | 2026-06-03 |
Squarer Ron Director · Common Shares · 2026-06-03 | Tax | 15.2K | $47K | 2026-06-03 | 2026-06-03 |
BIZZARI JEAN-PIERRE Director · Common Shares · 2026-06-03 | Tax | 12.6K | $39K | 2026-06-03 | 2026-06-03 |
Monges Viviane Director · Common Shares · 2026-06-03 | Tax | 2.6K | $8K | 2026-06-03 | 2026-06-03 |
Sandor Victor Director · Common Shares · 2026-06-03 | Tax | 12.6K | $39K | 2026-06-03 | 2026-06-03 |
Coughlin Timothy Director · Common Shares · 2026-06-01 | Grant | 45K | $0 | 2026-06-01 | 2026-06-03 |
BIZZARI JEAN-PIERRE Director · Common Shares · 2026-06-01 | Grant | 45K | $0 | 2026-06-01 | 2026-06-03 |
Sandor Victor Director · Common Shares · 2026-06-01 | Grant | 45K | $0 | 2026-06-01 | 2026-06-03 |
SEC filings
EDGAR filings in ADCT · 8 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.